KNSA vs WAT: fair value comparison
Kiniksa Pharmaceuticals International, plc and Waters Corporation · Updated 2026-08-31
Both currently screen as fairly valued on TickrTrends' Forward Fair Value model. Within Healthcare, KNSA currently sits closer to the top of our discount ranking.
| KNSA | WAT | |
|---|---|---|
| Verdict | Fairly valued | Fairly valued |
| Last price | $73.41 | $414.69 |
| 12-month range | $34.28–$73.41 | $296.48–$397.79 |
| Sector rank | #58 of 113 Healthcare | #61 of 113 Healthcare |
| Quality grade | D | D |
| Momentum grade | — | A |
| Leverage | Low | Moderate |
| Margin trend | — | Stable |
| Revenue growth | — | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | — | Overvalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: KNSA fair value analysis · WAT fair value analysis